Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01657110
Other study ID # PRJ-006245
Secondary ID
Status Completed
Phase Phase 2
First received August 1, 2012
Last updated January 27, 2015
Start date December 2012
Est. completion date December 2014

Study information

Verified date January 2015
Source The University of Western Australia
Contact n/a
Is FDA regulated No
Health authority Australia: Human Research Ethics CommitteeAustralia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

Mild to moderate facial acne is an extremely common disease of teenagers and young adults. This pilot study will investigate whether treatment with a gel containing tea tree oil reduces numbers of acne lesions and improves acne in twenty otherwise healthy consenting participants. The hypothesis is that treatment with tea tree oil gel will result in a significant improvement in acne after 12 weeks of treatment.


Description:

Tea tree oil is the essential oil obtained from the Australian plant Melaleuca alternifolia. The oil has been used in Australia for many decades as a topically applied antiseptic and has been used to treat bites, stings, cuts and grazes. Many studies have shown that tea tree oil has both antimicrobial and anti-inflammatory activity in the laboratory. In addition, clinical trials have demonstrated that the oil can help in treating conditions such as dandruff, tinea, colonisation with methicillin resistant Staphylococcus aureus (MRSA) in the nose and acne. Together, these laboratory and clinical studies indicate that tea tree oil can potentially be used to treat relatively minor skin infections or diseases.

This pilot study aims to investigate whether a commercially available gel containing tea tree oil is effective for treating mild to moderate facial acne. A minimum of 18 participants that meet the inclusion and exclusion criteria will be enrolled in the study. Participants will be instructed to apply the tea tree oil gel each morning and night for 12 weeks and their acne will be assessed after 4, 8 and 12 weeks of treatment. Acne severity will be measured by (1) counting the numbers of lesions (pimples) on the face and (2) assigning an overall acne severity score. The lesion counts and severity scores at 4, 8 and 12 weeks will be compared to the baseline count to evaluate whether the acne is improving.

Potential benefits to participants, and of the study, are that their acne may improve as a result of treatment and that the results of the study may provide evidence that a commercially available product is effective for treating acne. There are many over-the-counter topically applied products available for treating acne. Two of the most common active ingredients are benzoyl peroxide and salicylic acid. Benzoyl peroxide is an antibacterial agent that works by killing the P. acnes bacterium on the skin. Although it is relatively effective for treating acne, it can also be quite irritating, especially when patients first start to use it. Salicylic acid acts by helping to unblock pores and remove excess dead skin thus helping pimples to heal more quickly. However, it is generally not as effective as benzoyl peroxide. One previous study has shown that a gel containing 5% tea tree oil performed similarly to benzoyl peroxide for reducing pimples, suggesting that it warrants further study.

Since a small percentage of people (approximately 1.4%) are allergic to tea tree oil all participants will be monitored for any reactions to the study product. Tea tree oil allergy typically manifests as redness and swelling and the site of application. This is one of the possible risks to participants, however, given the small numbers of study participants the likelihood of one or more participants having a reaction to the oil is low. Another possible risk is that participants may not benefit from the treatment and that their acne may not improve.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 45 Years
Eligibility Inclusion Criteria:

1. Aged 16 - 45 years

2. Mild to moderate facial acne with 10 - 100 lesions

3. Investigator Global Assessment score of at least 2

4. Able to comply with the requirements of the protocol and attend the outpatients clinic at 2, 4, 8 and 12 weeks

5. Able to provide written informed consent

Exclusion Criteria:

1. More than 2 acne nodules

2. Allergy to tea tree oil or any component of the study drug

3. Current skin disease (other than acne)

4. Facial hair that may obscure acne lesions

5. Use of topical or systemic steroids within the last 2 or 4 weeks, respectively

6. Use of topical or systemic antibiotics within the last 2 or 4 weeks, respectively

7. Use of topical acne treatments (eg. benzoyl peroxide, salicylates, retinoids) within the last 2 weeks

8. Use of systemic retinoids within the past 6 months

9. Procedures on the face such as peels, laser therapy or microdermabrasion within the past 4 weeks

10. Women who are pregnant or breastfeeding

11. Women of childbearing potential not using a reliable contraceptive method. Participants taking oral contraceptives must have been taking their current contraceptive for the previous 3 months and must agree to continue with it until study completion.

12. Participation in another clinical trial during the last 12 weeks

13. Concurrent diseases which exclude the administration of therapy as outlined by the study protocol

14. Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study and/or likely to cause death within the study duration

15. Chronic lung disease with hypoxemia

16. Myocardial infarction during the last 6 months

17. Non-compensated heart failure

18. Severe non-compensated hypertension

19. Severe non-compensated diabetes mellitus

20. Severe psychiatric disease

21. Known HIV or active chronic hepatitis B or C infection

22. Subjects who, in the opinion of the investigator, are not likely to complete the study for what ever reason.

23. Subjects who, in the opinion of the investigator, abuse alcohol or drugs

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Tea tree oil
Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.

Locations

Country Name City State
Australia Hollywood Private Hospital Perth
Australia Royal Perth Hospital Perth Western Australia

Sponsors (3)

Lead Sponsor Collaborator
The University of Western Australia Hollywood Private Hospital, Royal Perth Hospital

Country where clinical trial is conducted

Australia, 

References & Publications (1)

Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev. 2006 Jan;19(1):50-62. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Mean tolerability score Mean tolerability will be determined as the average of the following;
Erythema
Scaling
Peeling
Burning
Induration
Dryness
These six parameters will be measured using a 5-point scale (0: None, 1: Minimal, 2: Mild, 3: Moderate, 4: Severe). Mean tolerability will be the average of these scores.
12 weeks Yes
Other The frequency of adverse events Any local or systemic adverse events will be recorded including the type of reaction and severity (on a 5-point severity scale where 0 = none and 4 = severe). 12 weeks Yes
Primary Lesion numbers Numbers of inflamed and non-inflamed facial lesions will be counted. 12 weeks No
Primary Investigator Global Assessment A 5-point severity scale (0-4) will be used to give an overall acne grade.
0: Clear skin with no lesions
Almost clear; rare lesions
Mild severity; some non-inflammatory lesions with no more than a few inflammatory lesions
Moderate severity; up to many non-inflammatory lesions and may have some inflammatory lesions
Severe; up to many noninflammatory and inflammatory lesions but no more than a few nodular lesions
12 weeks No
Secondary Decreased non-inflammatory lesion count Decrease in numbers of non-inflammatory lesions from baseline 12 weeks No
Secondary Decreased inflammatory lesion count Decrease in inflammatory lesion count from baseline 12 weeks No
Secondary Decrease in perceived facial oiliness Decrease in perceived facial oiliness from baseline 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3